Over 1 Year Ago
1 Min Read
NTLA is down -12%. Find out why the stock dipped today.
Shares of Intellia Thera CS (NTLA) are trading -12% lower at a price of $60.68 at the time of this writing. While it's a slightly pessimistic day for the Health Care sector in general, the stock is moving less than it's peers.
The stock's price seems to be coming back to earth after yesterday's positive news:
1) Intellia's stock was up 6% on data from an early-stage trial for its Crispr therapy.
2) The therapy, NTLA-2001, is targeted at heart-related issues in transthyretin ((ATTR)) amyloidosis.
3) The therapy cut serum TTR levels by more than two thirds in the trial.
Intellia Thera CS has been trading between a 52-week high of $158.84 and a 52-week low of $37.08. The stock has a market cap of $4.61 Billion.
Intellia Therapeutics is a leading clinical-stage genome editing company, focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creating enhanced engineered cells that can treat oncological and immunological diseases. Intellia's combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts it in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create new classes of therapeutic products.
The stock's price seems to be coming back to earth after yesterday's positive news:
1) Intellia's stock was up 6% on data from an early-stage trial for its Crispr therapy.
2) The therapy, NTLA-2001, is targeted at heart-related issues in transthyretin ((ATTR)) amyloidosis.
3) The therapy cut serum TTR levels by more than two thirds in the trial.
Intellia Thera CS has been trading between a 52-week high of $158.84 and a 52-week low of $37.08. The stock has a market cap of $4.61 Billion.
Intellia Therapeutics is a leading clinical-stage genome editing company, focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creating enhanced engineered cells that can treat oncological and immunological diseases. Intellia's combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts it in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create new classes of therapeutic products.
Recommended Articles
